Fidaxomicin has higher cure rate for C. difficile than other drug options, meta-analysis finds | ACP Gastroenterology Monthly
The study authors concluded that fidaxomicin could be considered as a first-line therapy for Clostridium difficile infection and that metronidazole should not be recommended.
H. pylori frequently resistant to usual antibiotic treatments, meta-analysis finds | ACP Gastroenterology Monthly
Primary and secondary resistance rates to clarithromycin, metronidazole, and levofloxacin were found to be at least 15%, the common threshold for choosing alternative empiric regimens, in almost all World Health Organization regions.
Short course of antibiotics worked as well as long for Enterobacteriaceae bacteremia | ACP Gastroenterology Monthly
Rates of mortality, recurrent bloodstream infections, and Clostridium difficile infections within 30 days were similar whether patients received eight or 15 days of antibiotics.
Among the recommendations, physicians should obtain a detailed clinical exposure history from all people with diarrhea, and patients who have fever or bloody diarrhea should be evaluated for enteropathogens that may respond to antimicrobial agents.
Updated guidelines for C. diff infection address fecal transplant, laboratory testing | ACP Gastroenterology Monthly
The guidelines recommend laboratory testing for C. diff only in patients with new-onset, unexplained diarrhea, defined as at least three unformed stools in 24 hours, among other guidance.
ACP Gastroenterology Monthly delivers a monthly summary of news in gastroenterology and hepatology, including the latest research, clinical guidelines, and FDA drug actions.
Review: In chronic hepatitis C virus infection, oral direct-acting antivirals have high sustained virologic response | ACP Gastroenterology Monthly
A commentary in ACP Journal Club noted that while screening and treating all patients with chronic hepatitis C virus (HCV) would be cost-effective and probably cost-saving, some payers are still resistant.
Nearly all patients in study achieved sustained virologic response after 12 weeks of new HCV treatment | ACP Gastroenterology Monthly
The drug combination appeared effective in adults with HCV genotypes 1, 2, 4, 5, or 6 infection and compensated cirrhosis in the industry-funded trial.
The primary outcome of the unblinded, randomized trial was the proportion of patients without recurrent Clostridium difficile infection 12 weeks after fecal transplant.
Antibiotic stewardship programs reduce incidence of C. difficile, multidrug-resistant infections, review finds | ACP Gastroenterology Monthly
The systematic review also found that antibiotic stewardship programs were significantly more effective when implemented along with infection control measures.